HRP20210228T1 - Amidi pirola kao inhibitori alfa v integrina - Google Patents
Amidi pirola kao inhibitori alfa v integrina Download PDFInfo
- Publication number
- HRP20210228T1 HRP20210228T1 HRP20210228TT HRP20210228T HRP20210228T1 HR P20210228 T1 HRP20210228 T1 HR P20210228T1 HR P20210228T T HRP20210228T T HR P20210228TT HR P20210228 T HRP20210228 T HR P20210228T HR P20210228 T1 HRP20210228 T1 HR P20210228T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- membered
- image
- carbocyclyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418833P | 2016-11-08 | 2016-11-08 | |
| EP17801236.5A EP3538528B1 (en) | 2016-11-08 | 2017-11-07 | Pyrrole amides as alpha v integrin inhibitors |
| PCT/US2017/060392 WO2018089360A1 (en) | 2016-11-08 | 2017-11-07 | Pyrrole amides as alpha v integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210228T1 true HRP20210228T1 (hr) | 2021-03-19 |
Family
ID=60409438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210228TT HRP20210228T1 (hr) | 2016-11-08 | 2017-11-07 | Amidi pirola kao inhibitori alfa v integrina |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10717736B2 (https=) |
| EP (1) | EP3538528B1 (https=) |
| JP (1) | JP7220653B2 (https=) |
| KR (1) | KR102515507B1 (https=) |
| CN (1) | CN110139864B (https=) |
| AU (1) | AU2017359030A1 (https=) |
| BR (1) | BR112019009293A2 (https=) |
| CA (1) | CA3042693A1 (https=) |
| CY (1) | CY1123893T1 (https=) |
| DK (1) | DK3538528T3 (https=) |
| EA (1) | EA201991124A1 (https=) |
| ES (1) | ES2852351T3 (https=) |
| HR (1) | HRP20210228T1 (https=) |
| HU (1) | HUE053620T2 (https=) |
| IL (1) | IL266469A (https=) |
| LT (1) | LT3538528T (https=) |
| MX (1) | MX377293B (https=) |
| PL (1) | PL3538528T3 (https=) |
| PT (1) | PT3538528T (https=) |
| RS (1) | RS61453B1 (https=) |
| SI (1) | SI3538528T1 (https=) |
| SM (1) | SMT202100089T1 (https=) |
| WO (1) | WO2018089360A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| ES2984394T3 (es) * | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| US11306084B2 (en) | 2016-12-29 | 2022-04-19 | Saint Louis University | Integrin antagonists |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| KR20230169979A (ko) * | 2021-03-10 | 2023-12-18 | 다이스 몰레큘스 에스브이, 인크. | 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| CA2309204A1 (en) | 1997-11-26 | 1999-06-03 | Dupont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists |
| CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20010042614A (ko) | 1998-04-10 | 2001-05-25 | 윌리암스 로저 에이 | 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체 |
| AU748621B2 (en) | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
| AUPP646598A0 (en) | 1998-10-12 | 1998-11-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing alpha-alanine derivative |
| DE19939981A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| PL355011A1 (en) * | 1999-11-08 | 2004-03-22 | Merck & Co, Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| GB0001447D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| CA2436130A1 (en) | 2001-01-29 | 2002-08-08 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted indoles and their use as integrin antagonists |
| AU2003259891A1 (en) | 2002-08-16 | 2004-03-19 | Janssen Pharmaceutica N.V. | Piperidinyl compounds that selectively bind integrins |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| ATE399542T1 (de) | 2003-10-01 | 2008-07-15 | Merck Patent Gmbh | Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| EP2526095A1 (en) * | 2010-01-19 | 2012-11-28 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| PT2953948T (pt) * | 2013-02-07 | 2017-12-12 | Scifluor Life Sciences Inc | Antagonistas de integrina fluorada |
| GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
-
2017
- 2017-11-07 HR HRP20210228TT patent/HRP20210228T1/hr unknown
- 2017-11-07 JP JP2019523772A patent/JP7220653B2/ja active Active
- 2017-11-07 PT PT178012365T patent/PT3538528T/pt unknown
- 2017-11-07 KR KR1020197016078A patent/KR102515507B1/ko active Active
- 2017-11-07 DK DK17801236.5T patent/DK3538528T3/da active
- 2017-11-07 SM SM20210089T patent/SMT202100089T1/it unknown
- 2017-11-07 CA CA3042693A patent/CA3042693A1/en not_active Abandoned
- 2017-11-07 WO PCT/US2017/060392 patent/WO2018089360A1/en not_active Ceased
- 2017-11-07 BR BR112019009293A patent/BR112019009293A2/pt not_active Application Discontinuation
- 2017-11-07 AU AU2017359030A patent/AU2017359030A1/en not_active Abandoned
- 2017-11-07 LT LTEP17801236.5T patent/LT3538528T/lt unknown
- 2017-11-07 RS RS20210206A patent/RS61453B1/sr unknown
- 2017-11-07 HU HUE17801236A patent/HUE053620T2/hu unknown
- 2017-11-07 PL PL17801236T patent/PL3538528T3/pl unknown
- 2017-11-07 SI SI201730618T patent/SI3538528T1/sl unknown
- 2017-11-07 ES ES17801236T patent/ES2852351T3/es active Active
- 2017-11-07 MX MX2019005233A patent/MX377293B/es active IP Right Grant
- 2017-11-07 EA EA201991124A patent/EA201991124A1/ru unknown
- 2017-11-07 EP EP17801236.5A patent/EP3538528B1/en active Active
- 2017-11-07 US US16/347,826 patent/US10717736B2/en active Active
- 2017-11-07 CN CN201780082138.2A patent/CN110139864B/zh active Active
-
2019
- 2019-05-06 IL IL266469A patent/IL266469A/en unknown
-
2021
- 2021-02-23 CY CY20211100149T patent/CY1123893T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110139864B (zh) | 2022-08-23 |
| MX377293B (es) | 2025-03-07 |
| SMT202100089T1 (it) | 2021-03-15 |
| CY1123893T1 (el) | 2022-05-27 |
| IL266469A (en) | 2019-07-31 |
| LT3538528T (lt) | 2021-03-10 |
| HUE053620T2 (hu) | 2021-07-28 |
| SI3538528T1 (sl) | 2021-03-31 |
| EP3538528A1 (en) | 2019-09-18 |
| ES2852351T3 (es) | 2021-09-13 |
| WO2018089360A1 (en) | 2018-05-17 |
| CN110139864A (zh) | 2019-08-16 |
| JP2020500182A (ja) | 2020-01-09 |
| EP3538528B1 (en) | 2020-12-23 |
| DK3538528T3 (da) | 2021-02-15 |
| US10717736B2 (en) | 2020-07-21 |
| EA201991124A1 (ru) | 2019-10-31 |
| US20190256512A1 (en) | 2019-08-22 |
| MX2019005233A (es) | 2019-08-12 |
| KR102515507B1 (ko) | 2023-03-28 |
| PT3538528T (pt) | 2021-02-16 |
| AU2017359030A1 (en) | 2019-06-20 |
| JP7220653B2 (ja) | 2023-02-10 |
| PL3538528T3 (pl) | 2021-05-31 |
| KR20190076031A (ko) | 2019-07-01 |
| CA3042693A1 (en) | 2018-05-17 |
| BR112019009293A2 (pt) | 2019-07-30 |
| RS61453B1 (sr) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210228T1 (hr) | Amidi pirola kao inhibitori alfa v integrina | |
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| JP2020500182A5 (https=) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| AR072900A1 (es) | Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina | |
| HRP20240861T1 (hr) | Derivati 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dihlorofenil)-2-metilpirimidin-4(3h)-ona i srodni spojevi kao inhibitori ptpn11 (shp2) za liječenje raka | |
| ME02373B (me) | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze | |
| HRP20192147T1 (hr) | Metode i pripravci za uporabu u liječenju raka i smanjenju wnt posredovanih učinaka u stanici | |
| JP2016523974A5 (https=) | ||
| IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
| JP2011511840A5 (https=) | ||
| HRP20130041T1 (hr) | Terapijska sredstva | |
| JP2018519245A5 (https=) | ||
| JP2019532928A5 (https=) | ||
| ME02815B (me) | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze | |
| JP2009501724A5 (https=) | ||
| JP2016506960A5 (https=) | ||
| JP2015529235A5 (https=) | ||
| AR035720A1 (es) | Derivados de amida ,composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de quimioquinas | |
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| IN2014DN03063A (https=) | ||
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. |